The LEAN study is the first clinical trial of a glucagon-like peptide-1 (GLP-1) analogue in patients with nonalcoholic steatohepatitis (NASH). The class of drugs is used to treat type 2 diabetes mellitus. Read more.
Related Stories
$20 Million Scholarship Article in The Kansas City Star
KC Scholars partnership also in U.S. News and World Report … Read more
Geosciences Professor’s Research Cited in New York Times
Fengpeng Sun co-authored study on California wildfire seasons The 2015 … Read more
Bloch Faculty Interviewed on NBC Nightly News
Brent Never teaches about Kansas City’s racial dividing line Never … Read more